Severe PreeclampsiaNCT07861685
Role of Postpartum Furosemide in Recovery of Patients With Severe Preeclampsia
A study testing Furosemide and Potassium in people with Severe Preeclampsia, run by Lady Reading Hospital, Pakistan at 1 site in Pakistan.
Trial summary
This randomized controlled trial will compare oral furosemide with placebo for improving blood pressure control in women with severe preeclampsia after delivery. Participants will receive either 20 mg of furosemide or a placebo tablet once daily for 5 days, in addition to standard postpartum treatment for high blood… Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Severe Preeclampsia
- What is being tested?
- Furosemide and Potassium
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 434 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Oct 2026to 25 May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Women aged 18 to 45 years
- Any parity
- Gestational age >28 weeks based on LMP
- Severe preeclampsia as per the study operational definition
Who cannot join
- History of underlying cardiac disease during pregnancy or postpartum
- Pre-existing renal dysfunction or serum creatinine >1.2 mg/dL on medical record
- Significant hypokalemia (K <3 mEq/L) before enrollment
- Known rheumatologic disease or advanced diabetes
- History of allergy to furosemide or prior use of diuretics before randomization
- History of thyroid disorders or other medical illnesses that may interfere with blood pressure management
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site, 1 recruiting
- Recruiting
Lady Reading Hospital
Peshawar, Khyber Pakhtunkhwa, 25000
Dr Qandil Sattar, MBBS, +923436144247, qandil.sattar@lrh.edu.pk
Dr Syeda Wajeeha, MBBS, +923436144247, wajeeha.syed@lrh.edu.pk
About this study
Official title: Efficacy of Postpartum Furosemide in Patients With Severe Preeclampsia: A Randomized Controlled Trial
This randomized controlled trial will compare oral furosemide with placebo for improving blood pressure control in women with severe preeclampsia after delivery. Participants will receive either 20 mg of furosemide or a placebo tablet once daily for 5 days, in addition to standard postpartum treatment for high blood pressure. Blood pressure, symptoms, adverse events, and the need for additional antihypertensive medication will be monitored for 7 days after delivery. The study will assess whether adding furosemide helps achieve better postpartum blood pressure control compared with placebo.
Read the detailed description
Severe preeclampsia can be associated with persistent or worsening high blood pressure after delivery. This randomized, double-blind, placebo-controlled trial will evaluate the efficacy of oral furosemide as an add-on treatment for postpartum blood pressure control in women with severe preeclampsia.
The study will be conducted in the Department of Obstetrics and Gynaecology, Lady Reading Hospital (MTI), Peshawar. A total of 434 women will be randomized into two groups, with 217 participants in each group. The intervention group will receive oral furosemide 20 mg once daily for 5 days after delivery, while the control group will receive a placebo tablet once daily for 5 days. Both groups will receive standard postpartum antihypertensive management, including monitoring and labetalol when required.
Participants will be followed from delivery through 7 days postpartum. Blood pressure will be monitored daily, including assessment of severe-range hypertension, symptoms, adverse events, and the need for additional antihypertensive medication. The primary assessment of efficacy will be based on achieving blood pressure below 140/90 mmHg on two readings 48 hours apart, without systolic blood pressure reaching 160 mmHg or higher or diastolic blood pressure reaching 110 mmHg or higher, and without requiring an increase in antihypertensive medication through 7 days postpartum.
- Conditions
- Severe Preeclampsia
- Being tested
- Furosemide and Potassium, Placebo
- Keywords
- Postpartum hypertension, Postpartum blood pressure, Preeclampsia, Pregnancy-induced hypertension
- Medical subject headings
- Pre-Eclampsia, Hypertension, Pregnancy-Induced
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Furosemide and PotassiumDrug
Furosemide 20 mg tablet administered orally once daily for 5 days after delivery as an add-on to standard postpartum antihypertensive treatment.
PlaceboDrug
Placebo tablet administered orally once daily for 5 days after delivery, in addition to standard postpartum antihypertensive treatment, including blood pressure monitoring and labetalol when required.
| Study group | Role | What they receive |
|---|---|---|
| Furosemide Group | Experimental | Participants will receive furosemide 20 mg tablet orally once daily for 5 days after delivery, in addition to standard postpartum antihypertensive treatment, including labetalol when required. Receives: Drug: Furosemide and Potassium |
| Placebo Group | Placebo comparator | Participants will receive a placebo tablet orally once daily for 5 days after delivery, in addition to the same standard postpartum antihypertensive treatment provided to the furosemide group. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood pressure
Proportion of participants achieving blood pressure below 140/90 mmHg on two readings taken 48 hours apart, with no systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg, and no need for an increase in antihypertensive medication from delivery through 7 days postpartum.
Measured: From delivery through 7 days postpartum
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Oct 2026
- Study start1 Oct 2026
- Primary completion15 Mar 2027 (estimated)
- Study completion25 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Severe PreeclampsiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomly assigned to either the oral furosemide group or the placebo group and followed in parallel for 7 days postpartum.
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 434 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Lady Reading Hospital, Pakistan
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Dr. Wajeeha Syed, Lady Reading Hospital, Pakistan
- Investigators
- Dr Qandil Sattar, Principal investigator, Lady Reading Hospital PeshawarDr Syeda Wajeeha, Principal investigator, Lady Reading Hospital Peshawar
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07861685
- Sponsor's protocol ID
- 48/LRH/MTI
- Status last verified
- Oct 2026
- First submitted
- 1 Oct 2026
- Last updated
- 6 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The synopsis only states that participant information will be kept confidential and that access will be limited, with the ethics committee able to review the information when necessary.
Publications
Pagan M, Ounprpaseuth ST, Ghahremani T, Doiron T, Magann EF. Furosemide for postpartum blood pressure control in patients with hypertensive disorders. Eur J Obstet Gynecol Reprod Biol X. 2023 May 3;18:100195. doi: 10.1016/j.eurox.2023.100195. eCollection 2023 Jun.
PubMed 37214156Lopes Perdigao J, Lewey J, Hirshberg A, Koelper N, Srinivas SK, Elovitz MA, Levine LD. Furosemide for Accelerated Recovery of Blood Pressure Postpartum in women with a hypertensive disorder of pregnancy: A Randomized Controlled Trial. Hypertension. 2021 May 5;77(5):1517-1524. doi: 10.1161/HYPERTENSIONAHA.120.16133. Epub 2021 Feb 8.
PubMed 33550824Hup RJ, Paauw ND, Lely AT, Depmann M. Oral antihypertensive agents and diuretics in the management of hypertension in postpartum women: a systematic review and meta-analysis. BMJ Open. 2024 Dec 20;14(12):e086208. doi: 10.1136/bmjopen-2024-086208.
PubMed 39806714Veena P, Perivela L, Raghavan SS. Furosemide in postpartum management of severe preeclampsia: A randomized controlled trial. Hypertens Pregnancy. 2017 Feb;36(1):84-89. doi: 10.1080/10641955.2016.1239735. Epub 2016 Nov 11.
PubMed 27835048Steele DW, Adam GP, Saldanha IJ, Kanaan G, Zahradnik ML, Danilack VA, Stuebe AM, Peahl AF, Chen KK, Balk EM. Management of Postpartum Hypertensive Disorders of Pregnancy [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2023 May. Report No.: AHRQ 23-EHC012Report No.: PCORI(R) 2023-SR-02. Available from http://www.ncbi.nlm.nih.gov/books/NBK592560/
PubMed 37289921Keiseb J, Moodley J, Connolly CA. Comparison of the efficacy of continuous furosemide and low-dose dopamine infusion in preeclampsia/eclampsia-related oliguria in the immediate postpartum period. Hypertens Pregnancy. 2002;21(3):225-34. doi: 10.1081/PRG-120016787.
PubMed 12517329
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Postpartum Furosemide in Patients With Severe Preeclampsia: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07861685
- Acronym / sponsor ID
- 48/LRH/MTI
- Conditions
- Severe Preeclampsia
- Keywords
- Postpartum hypertension, Postpartum blood pressure, Preeclampsia, Pregnancy-induced hypertension
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 434 participants (estimated)
- Lead sponsor
- Lady Reading Hospital, PakistanOther government
- Study start
- 1 Oct 2026 (actual)
- Primary completion
- 15 Mar 2027 (estimated)
- Study completion
- 25 May 2027 (estimated)
- First posted
- 6 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized controlled trial will compare oral furosemide with placebo for improving blood pressure control in women with severe preeclampsia after delivery. Participants will receive either 20 mg of furosemide or a placebo tablet once daily for 5 days, in addition to standard postpartum treatment for high blood pressure. Blood pressure, symptoms, adverse events, and the need for additional antihypertensive medication will be monitored for 7 days after delivery. The study will assess whether adding furosemide helps achieve better postpartum blood pressure control compared with placebo.
Detailed description
Severe preeclampsia can be associated with persistent or worsening high blood pressure after delivery. This randomized, double-blind, placebo-controlled trial will evaluate the efficacy of oral furosemide as an add-on treatment for postpartum blood pressure control in women with severe preeclampsia.
The study will be conducted in the Department of Obstetrics and Gynaecology, Lady Reading Hospital (MTI), Peshawar. A total of 434 women will be randomized into two groups, with 217 participants in each group. The intervention group will receive oral furosemide 20 mg once daily for 5 days after delivery, while the control group will receive a placebo tablet once daily for 5 days. Both groups will receive standard postpartum antihypertensive management, including monitoring and labetalol when required.
Participants will be followed from delivery through 7 days postpartum. Blood pressure will be monitored daily, including assessment of severe-range hypertension, symptoms, adverse events, and the need for additional antihypertensive medication. The primary assessment of efficacy will be based on achieving blood pressure below 140/90 mmHg on two readings 48 hours apart, without systolic blood pressure reaching 160 mmHg or higher or diastolic blood pressure reaching 110 mmHg or higher, and without requiring an increase in antihypertensive medication through 7 days postpartum.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
- Model description
- Participants will be randomly assigned to either the oral furosemide group or the placebo group and followed in parallel for 7 days postpartum.
| Arm | Type | Receives |
|---|---|---|
| Furosemide Group | Experimental | Drug: Furosemide and PotassiumParticipants will receive furosemide 20 mg tablet orally once daily for 5 days after delivery, in addition to standard postpartum antihypertensive treatment, including labetalol when required. |
| Placebo Group | Placebo comparator | Drug: PlaceboParticipants will receive a placebo tablet orally once daily for 5 days after delivery, in addition to the same standard postpartum antihypertensive treatment provided to the furosemide group. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Women aged 18 to 45 years
- Any parity
- Gestational age >28 weeks based on LMP
- Severe preeclampsia as per the study operational definition
Key exclusion criteria (6 listed)
- History of underlying cardiac disease during pregnancy or postpartum
- Pre-existing renal dysfunction or serum creatinine >1.2 mg/dL on medical record
- Significant hypokalemia (K <3 mEq/L) before enrollment
- Known rheumatologic disease or advanced diabetes
- History of allergy to furosemide or prior use of diuretics before randomization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Furosemide and PotassiumFurosemide 20 mg tablet administered orally once daily for 5 days after delivery as an add-on to standard postpartum antihypertensive treatment. | Drug | Furosemide Group |
| PlaceboPlacebo tablet administered orally once daily for 5 days after delivery, in addition to standard postpartum antihypertensive treatment, including blood pressure monitoring and labetalol when required. | Drug | Placebo Group |
Primary outcome
Blood pressure
Time frame: From delivery through 7 days postpartum
Proportion of participants achieving blood pressure below 140/90 mmHg on two readings taken 48 hours apart, with no systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg, and no need for an increase in antihypertensive medication from delivery through 7 days postpartum.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2026.
- Background: PubMed 37214156Pagan M, Ounprpaseuth ST, Ghahremani T, Doiron T, Magann EF. Furosemide for postpartum blood pressure control in patients with hypertensive disorders. Eur J Obstet Gynecol Reprod Biol X. 2023 May 3;18:100195. doi: 10.1016/j.eurox.2023.100195. eCollection 2023 Jun.
- Background: PubMed 33550824Lopes Perdigao J, Lewey J, Hirshberg A, Koelper N, Srinivas SK, Elovitz MA, Levine LD. Furosemide for Accelerated Recovery of Blood Pressure Postpartum in women with a hypertensive disorder of pregnancy: A Randomized Controlled Trial. Hypertension. 2021 May 5;77(5):1517-1524. doi: 10.1161/HYPERTENSIONAHA.120.16133. Epub 2021 Feb 8.
- Background: PubMed 39806714Hup RJ, Paauw ND, Lely AT, Depmann M. Oral antihypertensive agents and diuretics in the management of hypertension in postpartum women: a systematic review and meta-analysis. BMJ Open. 2024 Dec 20;14(12):e086208. doi: 10.1136/bmjopen-2024-086208.
- Background: PubMed 27835048Veena P, Perivela L, Raghavan SS. Furosemide in postpartum management of severe preeclampsia: A randomized controlled trial. Hypertens Pregnancy. 2017 Feb;36(1):84-89. doi: 10.1080/10641955.2016.1239735. Epub 2016 Nov 11.
- Background: PubMed 37289921Steele DW, Adam GP, Saldanha IJ, Kanaan G, Zahradnik ML, Danilack VA, Stuebe AM, Peahl AF, Chen KK, Balk EM. Management of Postpartum Hypertensive Disorders of Pregnancy [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2023 May. Report No.: AHRQ 23-EHC012Report No.: PCORI(R) 2023-SR-02. Available from http://www.ncbi.nlm.nih.gov/books/NBK592560/
- Background: PubMed 12517329Keiseb J, Moodley J, Connolly CA. Comparison of the efficacy of continuous furosemide and low-dose dopamine infusion in preeclampsia/eclampsia-related oliguria in the immediate postpartum period. Hypertens Pregnancy. 2002;21(3):225-34. doi: 10.1081/PRG-120016787.
- Individual participant dataSharing planned: No. The synopsis only states that participant information will be kept confidential and that access will be limited, with the ethics committee able to review the information when necessary.
Related trials for Severe Preeclampsia
Not yet recruitingPhase 2
Furosemide vs Placebo in Severe Preeclampsia Postpartum
Severe Preeclampsia
RecruitingPhase 4
Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound
Preeclampsia, Preeclampsia Postpartum
Not yet recruitingPhase 4
Biomarkers in Management of Post Partum Preeclampsia
Preeclampsia Severe, Preeclampsia Postpartum
Not yet recruitingObservational study
Identification of Genes of Interest for Severe Forms of Preeclampsia
Preeclampsia, Severe Preeclampsia
Not yet recruiting
Algorithm-Based Timing of Delivery Using the sFlt-1/PlGF Ratio in Early-Onset Severe Preeclampsia. (MAP 2 Study : Management Based on Angiogenic Markers in Preeclampsia 2 Study )
Severe Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Dr Qandil Sattar principal investigator
Lady Reading Hospital Peshawar
Dr Syeda Wajeeha principal investigator
Lady Reading Hospital Peshawar
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Furosemide and Potassium in people with Severe Preeclampsia, run by Lady Reading Hospital, Pakistan at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dr Qandil Sattar, MBBS (+923436144247, qantil.sattar@lrh.edu.pk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood pressure (time frame: From delivery through 7 days postpartum). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07861685, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026; AzTrials last refreshed its copy on 8 Nov 2026.